CABG Preferable to PCI for Multivessel Disease in DiabeticsCABG Preferable to PCI for Multivessel Disease in Diabetics
The finding, adding fuel to an ongoing debate, was especially pronounced in those revascularized after being stabilized from acute coronary syndrome, says data covering 2007 to 2014. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 13, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Humacyte pulls down $150m for artificial blood vessels
Humacyte said today that it raised a $150 million Series B round it plans to use to back a Phase III trial of its Humacyl lab-grown blood vessel technology.
Research Triangle Park, N.C.-based Humacyte, which raised a $12 million Series A round back in 2010, uses a proprietary technology to engineer human tissues that can be shaped into tubes, sheets and other forms to treat vascular diseases. The Duke University spinout was founded in 2004 by Dr. Laura Niklason, a former Duke researcher.
The Series B round was led by a global consortium of new and existing backers, including Access Industries, Bangkok Bank Public, Brad...
Source: Mass Device - October 20, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Regenerative Medicine Vascular Humacyte Inc. Source Type: news
TUXEDO-India: Paclitaxel Stent Flops vs 'Limus' Even in DiabeticsTUXEDO-India: Paclitaxel Stent Flops vs 'Limus' Even in Diabetics
Confirmation that paclitaxel coronary stents, as it happens, aren't more effective in diabetics than those eluting everolimus also reinforces doubts about trials favoring CABG in diabetics, say some. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 16, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
No significant benefit found in new treatment method for coronary artery bypass surgery
A study looking at ways to reduce damage to heart muscle during coronary artery bypass graft surgery (CABG) found using remote ischaemic preconditioning (RIPC) treatment did not provide greater protection against events including stroke, heart attack and cardiovascular death.RIPC is a virtually cost free, non-pharmacological and non-invasive treatment. The process involves using a blood pressure... (Source: NIHR Evaluation, Trials and Studies News)
Source: NIHR Evaluation, Trials and Studies News - October 15, 2015 Category: American Health Source Type: news
TCT: Everolimus-Eluting Stents Superior for T2D
(MedPage Today) -- TUXEDO findings prompt second look at stent versus CABG debate (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 14, 2015 Category: Cardiology Source Type: news
